Trusted generic combination offers broad spectrum, cost-effective option to prevent heartworm disease in cats, kill fleas, and control intestinal parasites
FORT WORTH, TEXAS (January 12, 2022) – Vetoquinol USA announces Imoxi™ (imidacloprid + moxidectin) Topical Solution for Cats is now available.
“Imoxi for Cats joins our canine product of the same name, which was launched in 2021,” said Rebecca Peskin, National Marketing Manager for Vetoquinol USA. “Now, veterinarians can offer their feline patients the same combination of imidacloprid and moxidectin they already trust, but at a cost more owners can afford.”
Imoxi is a once-a-month topical formula trusted for broad-spectrum protection against fleas, heartworm, and intestinal parasites. It also is indicated to treat and control ear mite (Otodectes cynotis) infestations.
Imoxi is available in a ready-to-use solution that is approved for use in cats and kittens 9 weeks of age and older and weighing at least 2 lbs.
Imoxi is available to pet owners by prescription only. Veterinarians can purchase now through select distributors or by contacting their Vetoquinol representative.
CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
Dogs: WARNING: DO NOT ADMINISTER THIS PRODUCT ORALLY. For the first 30 minutes after application, ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Children should not come in contact with the application sites for two (2) hours after application. (See Contraindications, Warnings, Human Warnings and Adverse Reactions for more information.) Cats: Do not use on sick, debilitated, or underweight cats. Avoid oral ingestion. For full prescribing information, visit www.vetoquinolusa.com/imoxi-info.
About Vetoquinol USA
Headquartered in Fort Worth, Texas, Vetoquinol USA is owned by Vetoquinol S.A., an independent, family-owned French pharmaceutical company founded in 1933. Dedicated exclusively to animal health, Vetoquinol USA is focused on the development, production, and marketing of FDA, EPA, NASC, and AAFCO-regulated pharmaceutical, nutritional, and dermatological products for small and large animals.
1. Companion Animal Parasite Council (CAPC). (2011 June 21) Data Reveal Cats Need Better Protection Against Roundworm And Heartworm.https://capcvet.org/about-capc/news-events/data-reveal-cats-need-better-...
©2022 Vetoquinol USA, Inc. Vetoquinol, the Vetoquinol logo, and Imoxi are registered trademarks of Vetoquinol USA, Inc.
Latest news of vetoquinol
Vetoquinol launches VetPowerment™ employee engagement tool13 Mar 2023Helps practices retain and attract top talent to stop the cycle of burnout and understaffing
Vetoquinol Launches Simplera™ (florfenicol, terbinafine, mometasone furoate) Otic Solution for Dogs28 Sep 2022Offers practices a generic one-dose, veterinarian-administered ear infection treatment for dogs